<?xml version="1.0" encoding="UTF-8"?>
<p>The risks associated with convalescent plasma administration can be classified in two categories: known, which include immunological reactions (serum sickness), transfer of other infectious agents, and allergic reactions to serum constituents; and theoretical, which comprise development of antibody-dependent enhancement of infection phenomenon, prevention of the infection via a pathway that reduces the immune response, and these patients become susceptible to subsequent reinfection [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>,
 <xref rid="B148-jcm-09-02084" ref-type="bibr">148</xref>]. Further clinical studies are required to confirm the convalescent plasma effectiveness and safety profile.
</p>
